NTLX:TSXV, NeuroThera Labs Inc.
Why NTLX stock rose on November 10
NeuroThera Labs Inc. rose 123.6%
on Tuesday, November 10, 2026, on 3,910 shares, 9.2 times its average daily volume.
No headline about NTLX came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.
NTLX stock overview
NeuroThera Labs Inc. (NTLX:TSXV) closed at $3.55 on November 13, 2026,
up 5.34% on the day.
The stock trades 33.3% below its 52-week high of $5.32
and 120.5% above its 52-week low of $1.61.
Over the past year, it gained 53.7%.
NeuroThera Labs Inc. is part of the Health Care sector.
Key figures
- Price
- $3.55
- Day change
- +5.34%
- Volume
- 14,695
- Average volume
- 423
- Market cap
- 301M+
- 52-week range
- $1.61 – $5.32
- 50-day average
- $3.09
- 200-day average
- $2.95
Price action over the past year
In 252 trading sessions since November 13, 2025, NTLX closed higher on 22 days (9%).
Its best day was November 10, 2026 (+123.60%) and its worst was October 8, 2026 (-47.73%).
The stock moved 10% or more in a single session 27 times.
It opened at least 5% above the previous day's high 13 times.
Recent signals
NTLX news
-
Oct 22, 2026:
NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome
-
Oct 22, 2026:
SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome
-
Oct 8, 2026:
Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder
-
Oct 7, 2026:
SciSparc: Subsidiary NeuroThera Labs' CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company's Quantum Architecture
-
Sep 23, 2026:
NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration With Clearmind Covering LSD, Ketamine and Ibogaine Combinations
-
Sep 23, 2026:
SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
-
Sep 23, 2026:
Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
-
Sep 2, 2026:
SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
About NeuroThera Labs Inc.
Neurothera Labs Inc. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. Neurothera's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation, and SCI- 210 for the treatment of ASD and status epilepticus.
Similar stocks
Find more stocks like NTLX with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.